WolffACHammondMEHAllisonKH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. Arch Pathol Lab Med. 2018;142:1364-1382.
2.
VandenBempt IVan LooPDrijkoningenM, et al. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. J Clin Oncol. 2008;26:4869-4874.
3.
HolzschuhMACzyzZHaukeSInwaldECPolzerBBrockhoffG.HER2 FISH results in breast cancers with increased CEN17 signals using alternative chromosome 17 probes—reclassifying cases in the equivocal category. Histo-pathology. 2017;71:610-625.
4.
HannaWMRüschoffJBilousM, et al. HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity. Mod Pathol. 2014;27:4-18.
5.
MarchiòCLambrosMBGugliottaP, et al. Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J Pathol. 2009;219:16-24.
6.
VargaZTubbsRRWangZ, et al. Co-amplification of the HER2 gene and chromosome 17 centromere: a potential diagnostic pitfall in HER2 testing in breast cancer. Breast Cancer Res Treat. 2012;132:925-935.
7.
LeeKJangMHChungYR, et al. Prognostic significance of centromere 17 copy number gain in breast cancer depends on breast cancer subtype. Hum Pathol. 2017;61:111-120.
